Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국
목요일, 8월 27

Apogee Therapeutics Inc

APGENASDAQ
Trade with Public
Trade with Public
$134.95
0.10.07%
가까이에: Aug 26, 5:00 PM EST
$134.95
N/A
시간외: 4:00 PM EST
개요뉴스실적 전망이벤트목표가재무심리지분 현황비교옵션주식 보고서

Apogee Therapeutics Financials

Apogee Therapeutics (APGE) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Apogee Therapeutics Q2 EPS $(1.14) Misses $(1.05) Estimate

Apogee Therapeutics (NASDAQ:APGE) reported quarterly losses of $(1.14) per share which missed the analyst consensus estimate of $(1.05) by 8.57 percent. This is a 0.88 percent decrease over losses of $(1.13) per share
Benzinga Newsdesk

PRO
Apogee Therapeutics Q1 EPS $(1.06) Beats $(1.08) Estimate

Apogee Therapeutics (NASDAQ:APGE) reported quarterly losses of $(1.06) per share which beat the analyst consensus estimate of $(1.08) by 1.85 percent. This is a 11.58 percent decrease over losses of $(0.95) per share
Benzinga Newsdesk

PRO
Apogee Therapeutics Q1 2026 Net Loss $74.11M Vs. Loss Of $55.34M YoY, Cash, Cash Equivalents, Marketable Securities And Long-term Marketable Securities Were $1.3B As Of March 31, 2026, With Cash Runway Into 2029

Benzinga Newsdesk

PRO
Apogee Therapeutics Q4 EPS $(1.03) Beats $(1.04) Estimate

Apogee Therapeutics (NASDAQ:APGE) reported quarterly losses of $(1.03) per share which beat the analyst consensus estimate of $(1.04) by 1.25 percent. This is a 13.45 percent increase over losses of $(1.19) per share
Benzinga Newsdesk

PRO
Update: Apogee Therapeutics Q3 EPS $(1.11) Beats $(1.20) Estimate

Benzinga Newsdesk

PRO
Apogee Therapeutics Q3 2025 Net Loss Was $65M Vs. $49M YoY, $913M Cash, Cash Equivalents And Marketable Securities Supports Runway Into 2H 2028

Benzinga Newsdesk

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

Benzinga

Benzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved